EGFR and metastatic colorectal cancer: The standard of care for patients with metastatic colorectal cancer (mCRC) has evolved with combination chemotherapy regimens, including cytotoxic agents (e.g., fluoropyrimidine [FU], oxaliplatin [OX], and irinotecan [IRI]), angiogenesis inhibitors (e.g., bevacizumab, aflibercept, and ramucirumab), and anti-epidermal growth factor receptor (EGFR) antibodies (e.g., cetuximab, and panitumumab) for patients with RAS wild-type tumors.